Peptide Knowledge Base · Metabolic

Adipotide (FTPP): what it is, what the evidence says, and its real status

A high-risk research peptide that killed fat-tissue blood vessels in animals, and damaged kidneys doing it.

Can you actually get it?

Plain-English verdict: No availability record.

Regulatory status: No regulatory record.

How does Adipotide (FTPP) work?

A peptide that triggers apoptosis in the vasculature feeding white adipose tissue, effectively starving fat stores.

What it does — and what it does not do

What it does: Produced striking fat loss in animal models.

What it does not do: It is not proven or safe in humans, animal studies showed kidney toxicity.

How honest is the evidence?

Evidence grade D — Animal and lab evidence; human trials still to come.

preclinical only; animal renal toxicity documented

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: No credible human safety or efficacy data; renal toxicity is the headline risk.

WADA status: Not prohibited.

Who should not take it

Documented renal toxicity in animals; not characterized or safe for human use.

Sources

Barnhart et al., adipotide preclinical (Sci Transl Med 2011)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 18, 2026 · Peptós.LIFE · Not medical advice.